Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Difelikefalin (MR13A9) for Uremic Pruritus in Hemodialysis Patients
jRCT2080223210Phase 2
- Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Start
- May 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease-associated pruritus (CKD-aP), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) comparing Difelikefalin (MR13A9) IV with Placebo IV (2 arms).
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080223210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223210.